Trial Profile
Phase 2, Double-Blind, Placebo Controlled Clinical Trial of EPI-743 in Subjects With Cobalamin C Defect
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vatiquinone (Primary)
- Indications Homocystinuria; Methylmalonic acidaemia
- Focus Therapeutic Use
- 22 Apr 2017 Status changed from active, no longer recruiting to completed.
- 23 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Feb 2014 New trial record